We are analyzing https://link.springer.com/article/10.1007/s10549-005-9120-9.

Title:
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells | Breast Cancer Research and Treatment
Description:
Src kinase plays a central role in growth factor signalling, regulating a diverse array of cellular functions including proliferation, migration and invasion. Recent studies have demonstrated that Src activity is frequently elevated in human tumours and correlates with disease stage. We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Since tumours exhibiting elevated EGFR signalling may possess elevated levels of Src activity, we wished to investigate the role of Src in our MCF7 model of endocrine resistance. Src kinase activity was significantly elevated in tamoxifen-resistant (TamR) cells in comparison to wild type MCF7 cells. This increase was not due to elevated Src protein or gene expression. Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels. AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions. Furthermore, the use of this compound in conjunction with the EGFR inhibitor, gefitinib, was markedly additive towards inhibition of TamR cell motility and invasion. These observations suggest that Src plays a pivotal role in mediating the motile and invasive phenotype observed in endocrine-resistant breast cancer cells. The use of Src inhibitors in conjunction with EGFR inhibitors such as gefitinib may provide an effective method with which to prevent cancer progression and metastasis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, article, pubmed, cas, cancer, src, cell, cells, breast, kinase, growth, factor, receptor, epidermal, focal, biol, csrc, elevated, adhesion, parsons, motility, activation, phosphorylation, tyrosine, activity, human, resistance, mol, access, research, invasion, sci, privacy, cookies, content, tamoxifen, hiscox, morgan, green, migration, invasive, paxillin, carcinoma, kinases, res, chem, publish, search, cellular,

Topics {✒️}

endocrine-resistant breast cancer month download article/chapter altered cell–matrix adhesion integrin-stimulated cell migration c-src-mediated phosphorylation breast cancer cells epidermal growth factor lambert-van der brempt receptor tyrosine kinases possess elevated levels growth factor signalling human colon cancer growth factor signaling src kinase activity elevated src protein focal adhesion kinase src family kinases cell motility embo tyrosine kinase domain elevated c-src full article pdf nbt-ii cells endocrine resistance tamr cell motility c-src enhances src-family serves src-dependent phosphorylation kinase-deficient src src kinase contributes mitochondrial protein cytochrome cell types whilst invasive cell phenotypes primary colorectal carcinoma privacy choices/manage cookies prevent cancer progression therapeutic target related subjects cancer research activated src detectable c-src interactions tamoxifen-resistant cell sci 113 cell sci 117 cell sci 112 cell biol 148 article hiscox pp60c-src activation stat3 enhances sensitivity dna synthesis induced tamoxifen resistance

Questions {❓}

Baselga J, Why the epidermal growth factor receptor?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
         description:Src kinase plays a central role in growth factor signalling, regulating a diverse array of cellular functions including proliferation, migration and invasion. Recent studies have demonstrated that Src activity is frequently elevated in human tumours and correlates with disease stage. We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Since tumours exhibiting elevated EGFR signalling may possess elevated levels of Src activity, we wished to investigate the role of Src in our MCF7 model of endocrine resistance. Src kinase activity was significantly elevated in tamoxifen-resistant (TamR) cells in comparison to wild type MCF7 cells. This increase was not due to elevated Src protein or gene expression. Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels. AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions. Furthermore, the use of this compound in conjunction with the EGFR inhibitor, gefitinib, was markedly additive towards inhibition of TamR cell motility and invasion. These observations suggest that Src plays a pivotal role in mediating the motile and invasive phenotype observed in endocrine-resistant breast cancer cells. The use of Src inhibitors in conjunction with EGFR inhibitors such as gefitinib may provide an effective method with which to prevent cancer progression and metastasis.
         datePublished:2005-12-07T00:00:00Z
         dateModified:2005-12-07T00:00:00Z
         pageStart:263
         pageEnd:274
         sameAs:https://doi.org/10.1007/s10549-005-9120-9
         keywords:
            breast cancer
            endocrine-resistance
            invasion
            motility
            Src
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:97
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Stephen Hiscox
               affiliation:
                     name:Welsh School of Pharmacy
                     address:
                        name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Liam Morgan
               affiliation:
                     name:Welsh School of Pharmacy
                     address:
                        name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tim P. Green
               affiliation:
                     name:AstraZeneca Pharmaceuticals
                     address:
                        name:AstraZeneca Pharmaceuticals, Macclesfield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Denise Barrow
               affiliation:
                     name:Welsh School of Pharmacy
                     address:
                        name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julia Gee
               affiliation:
                     name:Welsh School of Pharmacy
                     address:
                        name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name: Robert I. Nicholson
               affiliation:
                     name:Welsh School of Pharmacy
                     address:
                        name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells
      description:Src kinase plays a central role in growth factor signalling, regulating a diverse array of cellular functions including proliferation, migration and invasion. Recent studies have demonstrated that Src activity is frequently elevated in human tumours and correlates with disease stage. We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Since tumours exhibiting elevated EGFR signalling may possess elevated levels of Src activity, we wished to investigate the role of Src in our MCF7 model of endocrine resistance. Src kinase activity was significantly elevated in tamoxifen-resistant (TamR) cells in comparison to wild type MCF7 cells. This increase was not due to elevated Src protein or gene expression. Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels. AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions. Furthermore, the use of this compound in conjunction with the EGFR inhibitor, gefitinib, was markedly additive towards inhibition of TamR cell motility and invasion. These observations suggest that Src plays a pivotal role in mediating the motile and invasive phenotype observed in endocrine-resistant breast cancer cells. The use of Src inhibitors in conjunction with EGFR inhibitors such as gefitinib may provide an effective method with which to prevent cancer progression and metastasis.
      datePublished:2005-12-07T00:00:00Z
      dateModified:2005-12-07T00:00:00Z
      pageStart:263
      pageEnd:274
      sameAs:https://doi.org/10.1007/s10549-005-9120-9
      keywords:
         breast cancer
         endocrine-resistance
         invasion
         motility
         Src
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:97
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Stephen Hiscox
            affiliation:
                  name:Welsh School of Pharmacy
                  address:
                     name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Liam Morgan
            affiliation:
                  name:Welsh School of Pharmacy
                  address:
                     name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tim P. Green
            affiliation:
                  name:AstraZeneca Pharmaceuticals
                  address:
                     name:AstraZeneca Pharmaceuticals, Macclesfield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Denise Barrow
            affiliation:
                  name:Welsh School of Pharmacy
                  address:
                     name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julia Gee
            affiliation:
                  name:Welsh School of Pharmacy
                  address:
                     name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name: Robert I. Nicholson
            affiliation:
                  name:Welsh School of Pharmacy
                  address:
                     name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:97
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Welsh School of Pharmacy
      address:
         name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
         type:PostalAddress
      name:Welsh School of Pharmacy
      address:
         name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
         type:PostalAddress
      name:AstraZeneca Pharmaceuticals
      address:
         name:AstraZeneca Pharmaceuticals, Macclesfield, UK
         type:PostalAddress
      name:Welsh School of Pharmacy
      address:
         name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
         type:PostalAddress
      name:Welsh School of Pharmacy
      address:
         name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
         type:PostalAddress
      name:Welsh School of Pharmacy
      address:
         name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Stephen Hiscox
      affiliation:
            name:Welsh School of Pharmacy
            address:
               name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Liam Morgan
      affiliation:
            name:Welsh School of Pharmacy
            address:
               name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
               type:PostalAddress
            type:Organization
      name:Tim P. Green
      affiliation:
            name:AstraZeneca Pharmaceuticals
            address:
               name:AstraZeneca Pharmaceuticals, Macclesfield, UK
               type:PostalAddress
            type:Organization
      name:Denise Barrow
      affiliation:
            name:Welsh School of Pharmacy
            address:
               name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
               type:PostalAddress
            type:Organization
      name:Julia Gee
      affiliation:
            name:Welsh School of Pharmacy
            address:
               name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
               type:PostalAddress
            type:Organization
      name: Robert I. Nicholson
      affiliation:
            name:Welsh School of Pharmacy
            address:
               name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
      name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
      name:AstraZeneca Pharmaceuticals, Macclesfield, UK
      name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
      name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
      name:Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(166)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.57s.

LINK . SPRINGER . COM {}